marketplace and sustainability financial review corporate accounts and overview strategy and performance business segment review review and principal risks governance other information section 5 financial review and principal risks 43 Financial review 2 Group revenue Basic earnings per Ordinary Share $4.1bn 2% 81.3c 24.5% 2011: $4.3bn 2011: 65.3c 2012 2011 2010 Financial highlights $m $m $m Group revenue was $4,137m for the year ended Financial highlights i iii 31December 2012, representing a -3% decline compared Revenue 4,137 4,270 3,962 to 2011.
This comprised of underlying revenue growth of 2%, Underlying growth in revenue % 2% 4% 4% unfavourable currency translation of -2% and the disposal Trading profit 965 961 969 Underlying growth in trading profit % 6% 4 % 11% impact from the sale of the Clinical Therapies business Trading profit margin % 23.3% 22.5% 24.5% totalling -3%.
Operating profit 846 862 920 Attributable profit in 2012 was $729m compared to $582m Attributable profit for the year 729 582 615 in 2011.
Adjusted attributable profit calculated as set out in Adjusted attributable profit 679 664 654 Selected financial data on pages 156 to 157 increased 2% Basic earnings per Ordinary Share 81.3 65.3 69.3 to $679m in 2012, from $664m in 2011.
EPSA 75.7 74.5 73.6 Growth in EPSA % 2% 1% 12% Basic earnings per Ordinary Share were 81.3, compared to Dividends per Ordinary Share ii 26.1 17.40 15.82 65.3 for 2011.
EPSA as set out in Selected financial data Cash generated from operations 1,184 1,135 1,111 was 75.7 in 2012 compared to 74.5 for 2011, representing a Trading cash flow 999 838 825 2% increase.
Trading profit to cash conversion % 104% 87% 85% i Items shown in italics are non-GAAP measures.
Reconciliations to reported figures are on pages 44 to 46. ii The Board has proposed a final dividend of 16.2 US cents per share which together with the first interim dividend of 9.9 US cents makes a total for 2012 of 26.1 US cents.
The final dividend is expected to be paid, subject to shareholder approval, on 8May 2013 to shareholders on the Register of Members at the close of business on 19 April 2013. iii All items are $m unless otherwise indicated.
2 Underlying growth percentage after adjusting for the effect of a currency translation and disposal.
indd 43 26 02 2013 09:33 44 Smith & Nephew Annual Report 2012 Financial review continued Underlying growth in revenue reconciles to growth in revenue Measuring performance reported, the most directly comparable financial measure calculated Revenue in accordance with IFRS by making two adjustments, the constant Underlying growth in revenue is used to compare the revenue currency exchange effect and the acquisitions effect, described in a given year to the previous year on a like-for-like basis.
achieved by adjusting for the impact of sales of products acquired The constant currency exchange effect is a measure of the in material business combinations and for movements in exchange increase decrease in revenue resulting from currency movements rates.
Underlying growth in revenue is not presented in the accounts on non-US Dollar sales.
This is measured as the difference between prepared in accordance with International Financial Reporting the increase in revenue translated into US Dollars on a GAAP basis Standards IFRS and is therefore a measure not in accordance with ie current year revenue translated at the current year average rate, Generally Accepted Accounting Principles a non-GAAP measure.
prior year revenue translated at the prior year average rate and the The Group believes that the tabular presentation and reconciliation increase measured by translating current and prior year revenue into of reported revenue growth to underlying revenue growth assists US Dollars using the prior year closing rate.
investors in their assessment of the Groups performance in each The acquisitions effect is the measure of the impact on revenue business segment and for the Group as a whole.
from newly acquired business combinations.
This is calculated by Underlying growth in revenue is considered by the Group to be excluding the revenue from sales of products acquired as a result of an important measure of performance in terms of local functional a business combination consummated in the current year, with noncurrency since it excludes those items considered to be outside the US Dollar sales translated at the prior year average rate.
Additionally, influence of local management.
The Groups management uses this prior year revenue is adjusted to include a full year of revenue from non-GAAP measure in its internal financial reporting, budgeting and the sales of products acquired in those business combinations planning to assess performance on both a business segment and consummated in the previous year, calculated by adding back a consolidated Group basis.
Revenue growth at constant currency revenue from sales of products in the period prior to the Groups is important in measuring business performance compared to ownership.
These sales are separately tracked in the Groups internal competitors and compared to the growth of the market itself.
reporting systems and are readily identifiable.
The Group considers that revenue from sales of products acquired The disposals effect is the measure of the impact on revenue in material business combinations results in a step-up in growth in from the disposal of business operations during the year.
This is revenue in the year of acquisition that cannot be wholly attributed calculated by excluding the revenue from sales of products the to local managements efforts with respect to the business in the Group no longer sells as a result of the disposal in the current year, year of acquisition.
Depending on the timing of the acquisition, with non-US Dollar sales translated at the prior year average rate.
there will usually be a further step change in the following year.
Additionally, prior year revenue is adjusted to remove a full year Ameasure of growth excluding the effects of business combinations of revenue from the sales of products disposed.
These sales are also allows senior management to evaluate the performance and separately tracked in the Groups internal reporting systems and are relative impactof growth from the existing business and growth readily identifiable.
The process of making business acquisitions Reported revenue growth, the most directly comparable financial isdirected, approved and funded from the Group corporate centre measure calculated in accordance with IFRS, reconciles to underlying inline with strategic objectives.
growth in revenue as follows: The material limitation of the underlying growth in revenue measure 2012 2011 2010 is that it excludes certain factors, described above, which ultimately % % % have a significant impact on total revenues.
The Group compensates Reported revenue growth 3 8 5 for this limitation by taking into account relative movements in Constant currency exchange effect 2 4 1 exchange rates in its investment, strategic planning and resource allocation.
In addition, as the evaluation and assessment of Disposals effect 3 business acquisitions is not within the control of local management, Underlying revenue growth 2 4 4 performance of acquisitions is monitored centrally until the business Operating profit, the most directly comparable financial measure is integrated.
calculated in accordance with IFRS, reconciles to trading profit as The Groups management considers that the non-GAAP measure follows: of underlying growth in revenue and the GAAP measure of growth in revenue are complementary measures, neither of which 2012 2011 2010 management uses exclusively.
$m $m $m Operating profit 846 862 920 Acquisition related costs 11 Restructuring and rationalisation costs 65 40 15 Amortisation of acquisition intangibles and impairments 43 36 34 Legal claim see page 53 23 Trading profit 965 961 969 A reconciliation of reported revenue growth to underlying revenue growth, by business segment, can be found on pages 22 to 33.
indd 44 26 02 2013 09:33 marketplace and sustainability financial review corporate accounts and overview strategy and performance business segment review review and principal risks governance other information section 5 financial review and principal risks 45 The material limitation of these measures is that they exclude Trading profit significant income and costs that have a direct impact on current and Trading profit is a trend measure which presents the long-term prior years profit attributable to shareholders.
They do not, therefore, profitability of the Group excluding the impact of specific transactions measure the overall performance of the Group presented by the that management considers affects the Groups short-term GAAP financial measure of operating profit.
The Group presents this measure to assist investors in that no single measure enables it to assess overall performance their understanding of trends.
The Group has identified the following and therefore it compensates for the limitation of the trading profit items, where material, as those to be excluded from operating profit measure by considering it in conjunction with its GAAP equivalent.
when arriving at trading profit: acquisition and disposal related The gains or losses which are identified separately arise from items including amortisation of acquisition intangible assets and irregular events or transactions.
Such events or transactions are impairments: significant restructuring events: acquisition costs: and authorised centrally and require a strategic assessment which gains and losses resulting from legal disputes and uninsured losses.
includes consideration of financial returns and generation of A reconciliation of operating profit to trading profit, by business shareholder value.
Amortisation of acquisition intangibles will occur segment, can be found on pages 22 to 33. each year, whilst other excluded items arise irregularly depending on the events that give rise to such items.
Earnings per Ordinary share 2012 2011 2010 Adjusted earnings per Ordinary Share Basic 81.3 65.3 69.3 Growth in adjusted earnings per Ordinary Share EPSA is another Diluted 80.9 65.0 69.2 measure which presents the trend in the long-term profitability of the Group.
EPSA is not a recognised measure under IFRS and Adjusted: Basic 75.7 74.5 73.6 is therefore a non-GAAP financial measure.
The most directly Adjusted: Diluted 75.4 74.2 73.6 comparable financial measure calculated in accordance with IFRS is earnings per Ordinary Share.
Trading cash flow and trading profit to cash EPSA excludes the same impact of specific transactions or events that management considers affect the Groups short-term conversion ratio profitability, is used by the Group for similar purposes, and is subject Growth in trading cash flow and improvement in the trading profit to to the same material limitations, as set out and discussed in the cash conversion ratio are measures which present the trend growth above section on trading profit.
in the long-term cash generation of the Group excluding the impact Adjusted attributable profit represents the numerator used in of specific transactions or events that management considers affect the EPSA calculation.
Adjusted attributable profit is reconciled to the Groups short-term performance.
attributable profit, the most directly comparable financial measure in Trading cash flow is defined as cash generated from operations less accordance with IFRS, as follows: net capital expenditure but before acquisition related cash flows, Growth in trading profit and trading profit margin trading profit restructuring and rationalisation cash flows and cash flows arising expressed as a percentage of revenue are measures which present from legal disputes and uninsured losses.
Trading profit to cash the growth trend in the long-term profitability of the Group excluding conversion ratio is trading cash flow expressed as a percentage of the impact of specific transactions or events that management trading profit.
The nature and material limitations of these adjusted considers affect the Groups short-term profitability.
The Group items are discussed above.
presents these measures to assist investors in their understanding The Group presents those measures to assist investors in their of the trends.
The Groups international financial reporting budgets, understanding of trends.
The Groups internal financial reporting monthly reporting, forecasts, long-term planning and incentive plans budgets, monthly reporting, forecasts, long-term planning and focuses primarily on profit and earnings before these items.
Trading incentive plans focuses on cash generation before these items.
profit and trading profit margin are not recognised measures under Trading cash flow and trading profit to cash conversion ratio are not IFRS and are therefore non-GAAP financial measures.
recognised measures under IFRS and are therefore considered nonGAAP financial measures.
2012 2011 2010 $m $m $m The material limitation of this measure is that it could exclude Attributable profit for the year 729 582 615 significant cash flows that have had a direct impact on the current Acquisition related costs 11 and prior years financial performance of the Group.
It does not, therefore, measure the financial performance of the Group Restructuring and rationalisation expenses 65 40 15 presented by the GAAP measure of cash generated from operations.
Amortisation of acquisition intangibles and The Group considers that no single measure enables it to assess impairments 43 36 34 financial performance and therefore it compensates for the limitation Profit on disposal of net assets held for sale 251 of the trading cash flow measure by considering it in conjunction with Legal claim see page 53 23 the GAAP equivalents.
Cash flows excluded relate to irregular events Taxation on excluded items see page 104 82 17 10 or transactions including acquisition related costs, restructuring and Adjusted attributable profit 679 664 654 rationalisation costs and cash flows arising from legal disputes and uninsured losses.
indd 45 26 02 2013 09:33 46 Smith & Nephew Annual Report 2012 Financial review continued Trading cash flow reconciles to cash generated from operations, A more detailed analysis is included within the Revenue sections of the most directly comparable financial measure calculated in the individual business segments that follow on pages 22 and 33. accordance with IFRS, as follows: 2012 2011 2010 Cost of goods sold $m $m $m Cost of goods sold decreased by $70m to $1,070m from $1,140m Cash generated from operations 1,184 1,135 1,111 in 2011 which represents a 6% decrease.
Of this movement, 1% is Less: Capital expenditure 265 321 315 due to favourable currency translation movements.
The remaining Add: Cash received on disposal movement is largely attributable to the continued focus on costs, and offixedassets 8 partly attributable to the sale of the Clinical Therapies business in Add: Acquisition related costs 3 1 May 2012 which impacted both sales and cost of sales.
Add: Restructuring and rationalisation Further margin analysis is included within the Trading profit sections related expenditure 55 20 16 of the individual business segments that follow on pages 22 to 33.
Add: Legal settlement 22 Add: Macrotexture expenditure 3 5 Marketing, selling and distribution expenses Trading cash flow 999 838 825 Marketing, selling and distribution expenses decreased by $86m Trading profit 965 961 969 -6% to $1,440m from $1,526m in 2011.
The underlying movement Trading profit to cash conversionratio 104% 87% 85% of -4% is after adjusting for favourable currency movement of -2%.
Increased cost savings in Established markets were partly offset by investment in Emerging and International markets and promotion of 2012 Financial highlights new products particularly in Advanced Wound Management.
The following table sets out certain income statement data for the periods indicated: Administrative expenses 2012 2011 Administrative expenses increased by $35m 6% to $610m from $m $m $575m in 2011.
Favourable currency movements offset 2% of this Revenue i 4,137 4,270 increase.
The main factors contributing to the underlying movement Cost of goods sold ii 1,070 1,140 of 8% were an increase of $16m in amortisation on acquisition and Gross profit 3,067 3,130 other intangibles and an increase of $11m in acquisition costs.
Marketing, selling and distribution expenses 1,440 1,526 Administrative expenses iii, iv, v 610 575 Research and development expenses 171 167 Research and development expenses Operating profit i 846 862 Expenditure as a percentage of revenue increased by 0.2% to 4.1% in Net interest receivable payable 2 8 2012 2011 3.9%.
Actual expenditure was $171m in 2012 compared to $167m in 2011.
The Group continues to invest in innovative Other finance costs 3 6 technologies and products to differentiate it from competitors.
Share of profit from associates 4 Profit on disposal of net assets held for sale 251 Profit before taxation 1,100 848 Operating profit Taxation 371 266 Operating profit decreased by $16m to $846m from $862m in Attributable profit for the year 729 582 2011.
This comprised an increase of $2m in Advanced Surgical i Group revenue and operating profit are derived wholly from continuing operations Devices and a decrease of $18m in Advanced Wound Management.
and discussed on a segment basis on pages 22 to 33.
Advanced Surgical Devices started to see the benefits of its focus ii In 2012, $3m of restructuring and rationalisation expenses were charged to cost of on costs more than offsetting the additional restructuring expense goods sold 2011 $7m.
whilst Advanced Wound Management has continued to invest in iii 2012 includes $51m of amortisation of other intangible assets 2011 $42m.
new products throughout the year and also acquired Healthpoint iv 2012 includes $nil relating to legal provision 2011 $23m.
Biotherapeutics in December 2012, both increasing costs.
v 2 012 includes $62m of restructuring and rationalisation expenses, $43m relating to amortisation of acquisition intangibles and $11m acquisition related costs 2011 $33m of restructuring and rationalisation expenses and $36m relating to amortisation of acquisition intangibles.
Net interest receivable payable Net interest payable reduced by $10m from $8m payable in 2011 to a receivable of $2m in 2012.
This is a consequence of the overall Revenue reduction of borrowings within the Group, a reduction in the Group revenue decreased by $133m -3% from $4,270m in 2011 to applicable interest rates and the $7m interest receivable on the $4,137m in 2012.
Underlying revenue growth was 2% of which -2% Bioventus loan note issued following the disposal of the Clinical growth was attributable to unfavourable currency translation and -3% Therapies business.
was attributable to the effect of disposing of the Clinical Therapies business.
Advanced Surgical Devices revenues decreased by $143m -4%, underlying growth was 2% of which -2% was due to unfavourable currency translation and -4% due to the disposal of the Clinical Therapies business.
Advanced Wound Management revenues increased by $10m 1%, underlying growth was 4% with -3% due to unfavourable currency translation.
